Smac mimetic-induced upregulation of CCL2/MCP-1 triggers migration and invasion of glioblastoma cells and influences the tumor microenvironment in a paracrine manner

Neoplasia (United States)

Volumn 17, Issue 6, 2015, Pages 481-489

  Lindemann, Carina ^a   Marschall, Viola ^a   Weigert, Andreas ^a   Klingebiel, Thomas ^a   Fulda, Simone ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; CCL2 PROTEIN, HUMAN; DIABLO PROTEIN, HUMAN; MESSENGER RNA; MITOCHONDRIAL PROTEIN; OLIGOPEPTIDE; SIGNAL PEPTIDE; TUMOR MARKER;

ARTICLE; ASTROCYTE; CELL INVASION; CELL MIGRATION; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION PROFILING; GENE TARGETING; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN SECRETION; RECEPTOR UPREGULATION; SUPERNATANT; TUMOR MICROENVIRONMENT; APOPTOSIS; BIOMIMETICS; BRAIN NEOPLASMS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; METABOLISM; MITOCHONDRION; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BIOMARKERS, TUMOR; BIOMIMETICS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CCL2; COCULTURE TECHNIQUES; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; NF-KAPPA B; OLIGOPEPTIDES; PARACRINE COMMUNICATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84943160134     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2015.05.002     Document Type: Article

References (42)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, and Kleihues P (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114, 97-109.
2. Fulda S (2009). Tumor resistance to apoptosis. Int J Cancer 124, 511-515.
3. Fulda S, Wick W, Weller M, and Debatin KM (2002). Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8, 808-815.
4. Giese A, Bjerkvig R, Berens ME, and Westphal M (2003). Cost ofmigration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21, 1624-1636.
5. Fulda S and Vucic D (2012). Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 11, 109-124.
6. Fulda S (2014). Regulation of cell migration, invasion and metastasis by IAP proteins and their antagonists. Oncogene 33, 671-676.
7. Fulda S (2012). Novel promising IAP antagonist on the horizon for clinical translation. J Med Chem 55, 4099-4100.
8. Wagner L, Marschall V, Karl S, Cristofanon S, Zobel K, Deshayes K, Vucic D, Debatin KM, and Fulda S (2013). Smac mimetic sensitizes glioblastoma cells to temozolomide-induced apoptosis in a RIP1-and NF-kappaB-dependent manner. Oncogene 32, 988-997.
9. Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, andMaris JM, et al (2012). Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 58, 636-639.
10. Berger R, Jennewein C, Marschall V, Karl S, Cristofanon S, Wagner L, Vellanki SH, Hehlgans S, Rodel F, and Debatin KM, et al (2011). NF-{kappa}B is required for Smac mimetic-mediated sensitization of glioblastoma cells for {gamma}-irradiation-induced apoptosis. Mol Cancer Ther 10, 1867-1875.
11. Tchoghandjian A, Jennewein C, Eckhardt I, Rajalingam K, and Fulda S (2013). Identification of non-canonical NF-kappaB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells. Cell Death Dis 4, e564.
12. Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS, and Pieper RO (2001). Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res 61, 4956-4960.
13. Major EO, Miller AE, Mourrain P, Traub RG, de Widt E, and Sever J (1985). Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proc Natl Acad Sci U S A 82, 1257-1261.
14. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, and Wallweber HJ, et al (2007). IAP antagonists induce auto ubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131, 669-681.
15. Karl S, Pritschow Y, Volcic M, Hacker S, Baumann B, Wiesmuller L, Debatin KM, and Fulda S (2009). Identification of a novel pro-apopotic function of NF-kappaB in the DNA damage response. J Cell Mol Med 13, 4239-4256.
16. Eckhardt I, Roesler S, and Fulda S (2013). Identification of DR5 as a critical, NF-kappaB-regulated mediator of Smac-induced apoptosis. Cell Death Dis 4, e936.
17. Vogler M, Durr K, Jovanovic M, Debatin KM, and Fulda S (2007). Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 26, 248-257.
18. Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neeley CK, and Pienta KJ (2006). CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 8, 578-586.
19. Tang CH and Tsai CC (2012). CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-kappaB signaling pathway. Biochem Pharmacol 83, 335-344.
20. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA, Chunduru SK, Condon SM, and McKinlay M, et al (2007). IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131, 682-693.
21. Wang L, Du F, and Wang X (2008). TNF-alpha induces two distinct caspase-8 activation pathways. Cell 133, 693-703.
22. Deshmane SL, Kremlev S, Amini S, and Sawaya BE (2009). Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 29, 313-326.
23. Ueda A, Okuda K, Ohno S, Shirai A, Igarashi T, Matsunaga K, Fukushima J, Kawamoto S, Ishigatsubo Y, and Okubo T (1994). NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol 153, 2052-2063.
24. Takeshima H, Kuratsu J, Takeya M, Yoshimura T, and Ushio Y (1994). Expression and localization of messenger RNA and protein for monocyte chemoattractant protein-1 in human malignant glioma. J Neurosurg 80, 1056-1062.
25. Desbaillets I, Tada M, de Tribolet N, Diserens AC, Hamou MF, and VanMeir EG (1994). Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro. Int J Cancer 58, 240-247.
26. Kuratsu J, Yoshizato K, Yoshimura T, Leonard EJ, Takeshima H, and Ushio Y (1993). Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma. J Natl Cancer Inst 85, 1836-1839.
27. Platten M, Kretz A, Naumann U, Aulwurm S, Egashira K, Isenmann S, and Weller M (2003). Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann Neurol 54, 388-392.
28. Zhu X, Fujita M, Snyder LA, and Okada H (2011). Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol 104, 83-92.
29. Zhang J, Sarkar S, Cua R, Zhou Y, Hader W, and Yong VW (2012). A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis. Carcinogenesis 33, 312-319.
30. Egeblad M and Werb Z (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2, 161-174.
31. Vanderkerken K, Vande Broek I, Eizirik DL, Van Valckenborgh E, Asosingh K, Van Riet I, and Van Camp B (2002). Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells. Clin Exp Metastasis 19, 87-90.
32. Youngs SJ, Ali SA, Taub DD, and Rees RC (1997). Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer 71, 257-266.
33. Craig MJ and Loberg RD (2006). CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases. Cancer Metastasis Rev 25, 611-619.
34. Ridet JL, Malhotra SK, Privat A, and Gage FH (1997). Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci 20, 570-577.
35. Tchoghandjian A, Jennewein C, Eckhardt I, Momma S, Figarella-Branger D, and Fulda S (2014). Smac mimetic promotes glioblastoma cancer stem-like cell differentiation by activating NF-kappaB. Cell Death Differ 21, 735-747.
36. Eckhardt I, Weigert A, and Fulda S (2014). Identification of IRF1 as critical dual regulator of Smac mimetic-induced apoptosis and inflammatory cytokine response. Cell Death Dis 5, e1562.
37. Dogan T, Harms GS, Hekman M, Karreman C, Oberoi TK, Alnemri ES, Rapp UR, and Rajalingam K (2008). X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility. Nat Cell Biol 10, 1447-1455.
38. Oberoi TK, Dogan T, Hocking JC, Scholz RP, Mooz J, Anderson CL, Karreman C, Meyer zu Heringdorf D, Schmidt G, and Ruonala M, et al (2012). IAPs regulate the plasticity of cell migration by directly targeting Rac1 for degradation. EMBO J 31, 14-28.
39. Kim J, Ahn S, Ko YG, Boo YC, Chi SG, Ni CW, Go YM, Jo H, and Park H (2010). X-linked inhibitor of apoptosis protein controls alpha5-integrinmediated cell adhesion and migration. Am J Physiol Heart Circ Physiol 299, H300-309.
40. Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, and Altieri DC (2010). IAP regulation of metastasis. Cancer Cell 17, 53-64.
41. Lopez J, John SW, Tenev T, Rautureau GJ, Hinds MG, Francalanci F, Wilson R, Broemer M, Santoro MM, and Day CL, et al (2011). CARD-mediated autoinhibition of cIAP1's E3 ligase activity suppresses cell proliferation and migration. Mol Cell 42, 569-583.
42. Fulda S (2014). Molecular pathways: targeting inhibitor of apoptosis proteins in cancer-from molecular mechanism to therapeutic application. Clin Cancer Res 20, 289-295.